Skip to main content
S&P 5007,805.45-0.08%DOW51,670.10+0.03%NASDAQ27,204.38-0.15%BTC$83,172.00+2.24%ETH$2,498.69+3.33%GOLD$4,178.70+0.03%OIL$94.81+0.71%
Smart Investors Daily
SID Premium
CR

NASDAQ · CRBP

Corbus Pharmaceuticals Holdings, Inc.

Healthcare · Biotechnology

$5.27

Down-$0.49 (-9.30%)

Updated Oct 14, 2026, 12:14 AM

SID Score

2.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
121.59M
P/E ratio
-2.05
Dividend yield
0.00%
52-week range
$5.13 – $12.88
Volume
1.01M
Avg. volume
372.45K

Price performance · CRBP

CRBP price history

1M range · 0 trading sessions · Daily adjusted prices

CRBP does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CRBP news

The latest Smart Investors Daily articles mentioning CRBP.

Stock researchCompany · Overview

CRBP research

Overview

Company profile and research snapshot.

Company profile

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.33
Implied upside
—
Analysts
—
CRBP recent ratings
DateFirmRatingTarget
Sep 14, 2026HC Wainwright & Co.Buy—
Aug 7, 2026HC Wainwright & Co.Buy—
Aug 7, 2026OppenheimerOutperform—
Jun 23, 2026MizuhoOutperform—
Jun 17, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i

Yahoo · Sep 15, 2026

Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study

Corbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average b

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By